PT-141 Nasal Spray (10mg)

Research Overview

A cyclic heptapeptide melanocortin receptor agonist (primarily MC4R) developed from the Melanotan II scaffold. Unlike phosphodiesterase inhibitors, PT-141 acts centrally through hypothalamic melanocortin pathways, representing a mechanistically distinct approach to sexual function research.

Origin: Derived from Melanotan II; developed by Palatin Technologies

Mechanism of Action

• MC4R agonism (central, hypothalamic)

• MC3R partial agonism

• CNS-mediated arousal pathway

• Dopaminergic downstream signaling

• Independent of vascular mechanisms

Primary Research Areas

• Hypoactive sexual desire

• Melanocortin receptor pharmacology

• Central arousal pathways

• Female sexual dysfunction

Key Published Findings

• FDA-approved (as Vyleesi) for premenopausal HSDD (2019)

• Acts via central MC4R pathway, distinct from PDE5 inhibitors

• Demonstrated efficacy in both male and female models of sexual dysfunction

Research Protocol

Commonly studied routes: Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.

Storage

-20°C lyophilized, 2-8°C reconstituted

Important Notice

PT-141 Nasal Spray (10mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.